Clinical trial
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia…
NCT03920293 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT03920293 |
|---|---|
| Title | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis |
| Official title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Myasthenia Gravis |
| Intervention type | Biological, Drug |
| Interventions | Ravulizumab, Placebo |
| Enrollment | 175 |
| Start date | Mar 12, 2019 |
| Primary completion | May 11, 2021 |
| Completion | May 25, 2023 |
| First posted | Apr 18, 2019 |
| Last update posted | May 28, 2024 |
| Countries | Austria, Canada, Czechia, Denmark, France, Germany, Israel, Italy, Japan, Netherlands, Portugal, South Korea and 3 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: